Sales of weight-loss drugs in Brazil are reshaping pharmacy chains, now near a tenth of revenue, as a cheaper home-made version arrives this month.
Brazil · Business
Key Facts
—The shift. At the chain Pague Menos, these medicines made up 9.1 percent of sales in early 2026, a share that grew 167 percent in a year.
—Industry-wide. The drugs now account for roughly 8 to 9 percent of revenue at Brazil’s biggest pharmacy groups.
—The market. Analysts size the category near 11 billion reais in 2025 and see it climbing fast as prices fall.
India's market for cheaper anti-obesity drugs has surged tenfold. While demand is high, especially among those with diabetes,…
The landscape of India's anti-obesity drug market has reached a point of refinement. While there are affordable generic options,…
Alta incidência de obesidade, queda de preço do medicamento por causa dos genéricos e culto ao corpo explicam por que taxa de…
Transporting large quantities may be classified as a crime against public health
BRAZIL · ECONOMY Key Facts —The approval: Brazil's health regulator cleared Ozivy, the country's first home-grown version of…
With India’s semaglutide patent expiring on 20 March, about 50 branded generics are expected to enter the market.
